Follicular lymphoma: Prediction of POD and uplift of R maintenance therapy

Patient Basic Information

Patient ID *

Gender *

Female

Male

Age at First-line Treatment Initiation (years) *

Clinical Features

ECOG Score

0

1

2

3

4

B Symptoms

No

Yes

Pathological Grade

Grade 1-2

Grade 3a

Ann Arbor Stage

Stage I

Stage II

Stage III

Stage IV

Number of Involved Lymph Node Regions

Bone Marrow Involvement

No

Yes

Maximum Lesion Diameter (cm)

Maximum SUVmax of Lesions

Single Lymph Node >6cm

No

Yes

Laboratory Tests

White Blood Cells (WBC) (10^9/L)

Monocyte Absolute Count (10^9/L)

Lymphocyte Absolute Count (10^9/L)

Hemoglobin (HGB) (g/L)

Platelets (PLT) (10^9/L)

Lactate Dehydrogenase (LDH) (IU/L)

Beta-2 Microglobulin (β2-MG)

Treatment and Scoring

Reason for First-line Treatment Initiation

First-line Treatment Regimen

RCHOP

GCHOP

RB

GB

RCVP

GCVP

Response Evaluation After First-line Treatment

CR

PR

FLIPI-1 Score

0

1

2

3

4

5

FLIPI-2 Score

0

1

2

3

4

5

PRIMA-PI Score

0

1

2

Physician Assessment (Before Prediction)

Please assess the following questions based on your clinical experience before viewing the AI prediction results:

Expected 24-month Progression Risk Level

Very Low

Low

High

Very High

Expected R-Maintenance Benefit Level

Very Low (below 20% of population)

Low (below 50% of population)

High (above 50% of population)

Very High (above 80% of population)

Do you recommend R-maintenance for this patient?

Strongly Not Recommended

Not Recommended

Somewhat Recommended

Highly Recommended

Lymphoma Progression Risk Prediction and Rituximab Maintenance Benefit Assessment

Patient Basic Information

Clinical Features

Laboratory Tests

Treatment and Scoring

Physician Assessment (Before Prediction)